Key Drivers
- Cash Generation
- Margin Expansion
- Leverage Watch
AIAI Summary
BMY now looks like a cash-rich turnaround rather than a pure legacy-drug runoff play, with growth assets already making up 56% of revenue and supporting the dividend/debt reduction, but the investment still hinges on new launches scaling fast enough to offset Celgene-era litigation and patent erosion.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash Generation
- •Margin Expansion
- •Leverage Watch
BMY is delivering strong earnings, cash flow, and improving liquidity, but elevated leverage and a heavy intangible-asset mix keep the balance sheet the main risk.
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •Momentum fade
- •Support holding
Over the last month, BMY is still in a modest uptrend with higher lows, but momentum has cooled after the early-August peak near $65.89 and it now needs to hold the $63.5–$63.6 support zone to keep the bullish case intact.
Rally stalled after peaking near $65.89, followed by a short pullback
Sentiment & News
Key News Insights:
- •Growth portfolio strength
- •Raised guidance
- •Legacy-drug headwinds
Bristol Myers Squibb beat Q2 expectations, raised 2026 guidance, and saw strong market and analyst support as its growing newer-drug portfolio offsets legacy-drug declines despite ongoing generic and patent-expiry pressure.
The news is likely supportive for BMY in the near term, as improved earnings momentum and a stronger product mix outweigh lingering patent and generic concerns
Similar Companies in Healthcare
Other companies in the same sector with AI ratings